Abstract. In haemodialysis low-molecular-weight (LMW) heparin is increasingly used für anticoagulation. The advantages over unfractionated (UF) heparin are the lower bleeding risk and the lack of infiuence on lipid metabolism. However, no reliable and rapid method is available so rar to control the efficacy and safety of LMW heparin during haemodialysis. The specific anti-factor Xa (aXa) chromogenic substrate assays are laborious and time consuming. In the present study we have compared chromogenic assay with a coagulation assay (heptest), which was performed from plasma and whole-blood sampIes. The effects were compared with unfractionated heparin during haemodialysis. The aXa activity in the chromogenic S2222 assay ranged between 0.2 and 0.5 V/mI with UF heparin and between 0.4 and 0.8 V/mI with LMW heparin during haemodialysis. The coagulometric aXa activity in heptest assay from plasma was 0.6-1.0 V/mI with UF heparin and 1.2-2.0 V/mI with LMW heparin. The Heptest coagulation values from citrated whole blood sampIes ranged from 0.4 to 0.8 V/mI with UF heparin and from 0.8 to 1.4 U/ml with LMW heparin. The prolongation of the heptest clotting times with UF and LMW heparin was in the range of 4.4 für UF heparin and 5.2 für LMW heparin using the whole-blood assay. Heptest assay from plasma sampIes yielded prolongations of 6.1 with UF heparin and 6.6 with LMW heparin. The data show thai the coagulation assay is rapid and reproducible using plasma ar uncentrifuged whole-blood sampIes and is valid to monitor UF heparin or LMW heparin in patients undergoing chronic intermittent haemodialysis.
Introduction
Low-molecular-weight (LMW) heparins have beeil shown to be effective für anticoagulation in chronic Correspondence and offprinl requesls 10:Prof. Dr. med. J. Harenberg, 1. Medizinische Klinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer, 68167 Mannheim, Germany intermittent haemodialysis [1] [2] [3] [4] [5] . The advantages of LMW heparins over unfractionated (UF) heparins are a lower incidence of bleeding risk [6] , lower incidence ofthrombocytopenia [7, 8] , and improvement ofhyperlipidaemia [9, 10] . Patients on chronic intermittent haemodialysis orten suffer from an increased bleeding risk or hyperlipidaemia. In these patients LMW heparins may be of benefit.
The dosage of LMW heparin during haemodialysis has to be adapted to each patient. Measurement of LMW heparins requires a specific chromogenic substrate assays to determine the inhibition of factor Xa [9] [10] [11] . In contrast, unfractionated heparin is monitared using whole-blood clotting methods [12, 13] . These whole-blood clotting methods are not sensitive to LMW heparins and the chromogenic assays are time consuming and quite laborious. Therefore a sensitive, specific, reproducible and rapid in-vitra method is required to control the effects of LMW heparin in haemodialysis accurately.
An anti-factor Xa (aXa)-specific clotting method has beeil described using venous whole blood [14] . The sensitivity and specificity of the test system has beeil defined für unfractionated and LMW heparin [17] . The present paper reports the results of a randomized prospective trial to define the validity of the antifactor Xa coagulation assay für monitoring UF and LMW heparin in plasma and whole-blood sampIes from patients with chronic renal failure during haemodialysis.
Subjects and methods

Patients and dialysis protocol
Twenty of 28 patients on a chronic haemodialysis programme were eligible to take part in the study. Prior to inclusion all patients received UF heparin during haemodialysis. Patients were randomized to receive either UF heparin or LMW heparin für five consecutive dialysis procedures. Informed consent was obtained from the patients in the presence of a witness. Dialysis equipment was from Fresenius (Bad Homburg, Germany). Cuprophan (n = 10) or polysulphone membranes (n = 10) of hollow-fibre type with a surface area of 1.20 m2 were used für haemodialysis. Nineteen patients 11;) 1995 European Dialysis and Transplant Association-European Renal Association had Brescia-Cimino fistulae, Olle patient had a Goretex-shunt implant at the forearm. Cannulae with a diameter of 1.5 or 1.6 mm were used, fiow was between 200 and 300 ml/min. The fiow of the dialysate was 500 ml/min. Mean values and standard deviation of patients data are given in Table 1 . No relevant differences between the two treatment groups can be observed. Eight patients suffered from glomerulonephritis, four from diabetic nephropathy, Ollefrom chronic pyelonephritis, and Ollefrom cystic disease of the kidney. The origin of renal insufficiency was unclear in six patients. None of these patients suffered from malignant disease or other chronic diseases. Olle patient receiving erythropoietin had a haemoglobin of 18.8 g/dl and a haematocrit of 58%.
Six patients received lipid-lowering drugs, five received diuretics, six antihypertensive drugs, three digitalis, four insulin, and Olle patient oral antidiabetic drugs. No patient was treated with drugs with an infiuence on platelet aggregation, fibrinolysis, or anticoagulation other than the heparin administered during dialysis.
UF heparin was from Leo Pharmaceutical products (Denmark). LMW heparin Fragmin@ was from Kabi Plasma activated partial thromboplastin time (aPTT) was measured using the kaolin activated test system pathrombin (Behringwerke AG, Marburg, Germany) [15] . Thrombin clotting time was düne using a solution of 3 NIH units bovine thrombin/mI plasma (Behringwerke AG, Marburg, Germany). Antifactor Xa-like activity from plasma was measured with the heptest reagents (Haemachem, St Louis, USA) [16] . The chromogenic S 2222 substrate assay was performed in plasma as described before using a microtitre plate technique [17] .
The whole-blood clotting assay für aXa-like activity was düne as described earlier [16] . Standard curves für UF heparin and LMW heparin were proved using the Fourth International Standard für UF heparin and the First International Standard für LMW heparin in all anti-factorXa-specific test systems. UF and LMW heparin were expressed as units/ml (U /ml) on the basis of these standards. In addition the original coagulation values of the heptest assay are given. All coagulation tests have beeil düne by using KCl and KCIO coagulometers (Amelung, Lemgo, Germany). Table   Coag Statistical analysis
The coagulation values before haemodialysis were compared with those during haemodialysis using Wilcoxon paired comparison test. This test was chosen because the coagulation values were not normally distributed. The level of significance was P=O.OOI für heptest and the chromogenic S2222 assay. For APTT and thrombin clotting time a lower level of significance with 0.01 was chosen. All data are given as mean and standard deviation. The values are given as range, mean (x) and standard deviation (SD).
Monitoring ofheparins in haemodialysis
Results
Patients
The mean initial bolus of unfraetionated heparin was 2650 IV, followed by 36.6 IV/kg body-weight by eontinuous intravenous infusion. Low-moleeular heparin was given initially with 1750 IV as bolus followed by eontinuous intravenous infusion of 26.4 IV/kg bodyweight. Only in Ollepatient was minimal visible clot formation observed onee at the third study day in the dialyser upon applieation of VF as weIl as LMW heparin. Olle patient reeeived a bolus of 2500 IV followed by 32 IV/kg unfraetionated heparin by eontinuous infusion; 0.300 V/mI was measured with heptest and 0.182 V/mI with the ehromogenie assay S2222. The other patient reeeived 1600 IV LMW heparin as a bolus and 28 IV/kg as eontinuous infusion; 0.351 V/mI was determined in the heptest assay and 0.208 V/mI in the ehromogenie assay. Heparin regimens were not ehanged and clotting did not reoeeur. No haemorrhagie eomplieations oeeurred throughout the study period.
Coagulation values
The eoagulation values during haemodialysis with unfraetionated heparin are shown in Table 2 . Values are given as mean and standard deviation. Values 2 h after onset of haemodialysis represent the steady-state eonditions during eontinuous heparin administration. Heparin aetivities before administration are shown to be below 0.02 V/mI. During intravenous infusion of VF heparin the anti-faetor Xa aetivity measured by ehromogenie assay was 0.232::t0.1O3 V/mI. Vsing heptest eoagulation values of 0.926::t 0.393 V/mI were measured in plasma (P<O.OOI). With heptest ofwhole blood sampIes lower aetivities with a mean value of 0.522::t0.161 V/mI were found (P<O.OOI). The eoeffieients of variation are 44% using the S2222 method, 42% with heptest from plasma and 30% with heptest from whole blood. The aPTT and thrombin clotting time were found to be prolonged to 56.88::t8.9s and to 39.85::t 17.56 s, respeetively (P<O.OI). --HeptestPlasma -0-HeptestBlood ---n-aPTT Fig.1 . Mean values and standard deviation ofthe 10 patients during Jive haemodialyses; anticoagulation was performed with 2650 IU UF heparin as bolus injection followed by 36.6 IU/kg body weight by intravenous continuous infusion. Coagulation values of aPTT, heptest from plasma sampies land whole blood sampies 2 are given. Blood sampies were taken 2 h after starting haemodialysis. 
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Mean values and the standard deviation of aPTT, plasma heptest, and whole blood heptest are shown in Figure 1 für
OOI).
The differences between the three anti-factor Xa test systems during anticoagulation with LMW heparin were similar to those found during anticoagulation with unfractionated heparin (see Table 2 ). The coefficients of variation were 29% für the S2222 method, 24% für herlegt in plasma sampIes and 29% für wholeblood herlegt. Mean values and standard deviation of aPTT, heptest from plasma and herlegt from whole blood are given as original coagulation time values in Figure 2 für patients of the LMW heparin treatment group. The aPTT coagulation time was prolonged to 44:t 5 s (P<O.OI). Heptest values from plasma average to 160:t 34 s (P <0.01). Heptest values using whole blood samples were 11O:t14s (P<O.OOl). There was only minor variation between the 5 treatment days.
The prolongation of the clotting limes of each patient hag been expressed as the ratio of the clotting time in seconds during heparinization divided by the individual clotting time before heparinization. The individual ratios für herlegt values using whole blood, herlegt values using plasma samples, aPTT, and TCT are given as mean and standard deviation für unfractionated and LMW heparin in Table 4 . aPTT and TCT are prolonged by a ratio of 1.7 and 2.2 during heparinization with unfractionated heparin. The standard deviation was found to be rather low für both test systems. Vsing LMW heparin aPTT as weIl as TCT were found to be prolonged by a ratio of 1.2 and 1.3 Table 4 . Prolongation of the coagulation tests: heptest whole blood (w.b.), heptest from plasma sampies (PI.), aPTT and thrombin clotting time (TCT) are given respectively. The prolongation of the heptest clotting limes with unfractionated heparin and LMW heparin were in the range of 4.4 für unfractionated heparin and 5.2 für LMW heparin using the whole-blood clotting assay. Heptest assay from plasma sampIes yielded prolongations of 6.1 with unfractionated heparin and 6.6 with LMW heparin. This indicates that both test systems display comparable clotting time values with unfractionated and LMW heparin.
Discussion
Anticoagulation during haemodialysis with lowmolecular-weight heparin can be monitored by chromogenic substrate assays. Values of 0.6 to 1.0 aXa V/mI plasma are typically measured during effective anticoagulation [9, 10, 12, 13] . The aXa levels measured during anticoagulation with unfractionated heparins are somewhat tower. Heptest coagulation assay measures anti-factor Xa, anti-factor Xa-like activities and anti-thrombin activities in plasma sampIes or in whole blood sampIes. Therefore the coagulation values are higher compared with the anti-factor Xa results of the chromogenic assay. However, the data show that results of the heptest and the chromogenic S2222 assay remained during the five dialysis procedures within the range monitored during the first haemodialysis procedure. It can be concluded from these studies that both the specific anti-factor Xa chromogenic and coagulation assays from plasma and whole blood can be used für the monitoring of unfractionated heparin treatment during haemodialysis.
An important result of the present study is that centrifugation of blood sampIes is not necessary für the measurement of anti-factor Xa-like activity in these patients. Further results with samples from healthy subjects and patients on lang-term treatment with LMW heparin demonstrated high relationships of the chromogenic S2222 method with anti-factor Xa-like activity in plasma clotting assay [17] . In the present investigation assays succeed in demonstrating the anticoagulation of VFH and LMWH in patients on haemodialysis. The advantage of the whole-blood anti-factor Xa-like clotting assay is the fact that it can be used as The therapeutic range of the aPTT für anticoagulation with heparin in patients with recent deep-vein thrombosis is accepted to be a two-to threefold prolongation of the normal range [18] . No agreement has been reached so rar für therapeutic ranges of antifactor Xa and anti-factor Xa-like assays. Several studies have been published recently demonstrating the efficacy and safety of LMW heparin für treatment of recent deep-vein thrombosis [19] [20] [21] [22] . The measuremeßt of anti-factor Xa-like activity using the chromogenic and the coagulation anti-factor Xa assay shows an increase in anti-factor Xa activity with LMW heparin ranging from 0.6 to 1.0 anti-factor Xa UIm!. Anticoagulation effects during haemodialysis with heparin and low-molecular-weight heparin in the present study were comparable to figures reported für treatment of deep-vein thrombosis. Thus the present data indicate thai the chromogenic and the coagulation anti-factor Xa assay give reproducible and valid results für monitoring heparinization~with UF and LMW heparin during haemodialysis. Studies employing coagulometric test systems in patient treatment with LMWH during haemodialysis have shown a dose relationship between the anti-factor Xa activity measured and the in-vivo anticoagulant response. Therefore measurements of the anti-factor Xa levels in plasma should be adequate für monitoring the concentration of heparins in patients with chronic renal failure during haemodialysis. Moreover, measuremeßt of anti-factor Xa activity in whole blood is suggested as a rapid and reliable bedside method für monitoring of heparin treatment during haemodialysis. Additional studies are now required to correlate the anti-factor Xa activity and the thrombin generation inhibition during haemodialysis.
